ECSP22031078A - Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia card?aca - Google Patents

Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia card?aca

Info

Publication number
ECSP22031078A
ECSP22031078A ECSENADI202231078A ECDI202231078A ECSP22031078A EC SP22031078 A ECSP22031078 A EC SP22031078A EC SENADI202231078 A ECSENADI202231078 A EC SENADI202231078A EC DI202231078 A ECDI202231078 A EC DI202231078A EC SP22031078 A ECSP22031078 A EC SP22031078A
Authority
EC
Ecuador
Prior art keywords
heart failure
angiotensin
receptor antagonist
treatment
nep inhibitor
Prior art date
Application number
ECSENADI202231078A
Other languages
English (en)
Inventor
Jingchao Sun
Xiaolong Jing
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of ECSP22031078A publication Critical patent/ECSP22031078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los usos de un complejo de un metabolito antagonista del receptor de angiotensina II y un inhibidor de NEP para la insuficiencia card?aca, se relacionan espec?ficamente los usos del complejo en la preparaci?n de un medicamento para su uso en la insuficiencia card?aca con fracci?n de expulsi?n reducida (HFrEF).
ECSENADI202231078A 2019-09-20 2022-04-19 Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia card?aca ECSP22031078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910890853 2019-09-20
CN202010901984 2020-09-01

Publications (1)

Publication Number Publication Date
ECSP22031078A true ECSP22031078A (es) 2022-08-31

Family

ID=74883393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202231078A ECSP22031078A (es) 2019-09-20 2022-04-19 Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia card?aca

Country Status (13)

Country Link
US (1) US12508246B2 (es)
EP (1) EP4032532A4 (es)
JP (1) JP7316449B2 (es)
KR (1) KR102752382B1 (es)
CN (2) CN115487175B (es)
AU (1) AU2020348813B2 (es)
CA (1) CA3151788A1 (es)
CO (1) CO2022004910A2 (es)
EC (1) ECSP22031078A (es)
MX (1) MX2022003408A (es)
TW (1) TWI809313B (es)
WO (1) WO2021052441A1 (es)
ZA (1) ZA202204370B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115487175B (zh) 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
TWI894333B (zh) * 2020-08-17 2025-08-21 大陸商深圳信立泰藥業股份有限公司 血管收縮素ii受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203284A1 (en) * 1998-11-06 2004-08-12 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP1778267A4 (en) * 2004-07-16 2010-01-06 Nitromed Inc COMPOSITIONS AND METHODS RELATED TO HEART ERROR
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR20110128865A (ko) 2009-04-01 2011-11-30 미쓰이 가가쿠 가부시키가이샤 올레핀의 제조 방법
AR089954A1 (es) 2012-02-15 2014-10-01 Theravance Inc Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
ES2968541T3 (es) 2013-08-26 2024-05-10 Novartis Ag Tratamiento de enfermedades cardiovasculares
CN105503760A (zh) 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
EP4570314A3 (en) * 2015-05-11 2025-09-10 Novartis AG Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
WO2017006254A1 (en) * 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105669581B (zh) 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
CN108473474B (zh) * 2016-01-20 2022-02-11 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
JP7306828B2 (ja) * 2016-03-08 2023-07-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 結晶性（２ｓ，４ｒ）－５－（５’－クロロ－２’－フルオロ－［１，１’－ビフェニル］－４－イル）－２－（エトキシメチル）－４－（３－ヒドロキシイソオキサゾール－５－カルボキサミド）－２－メチルペンタン酸およびその使用
CN108619138B (zh) * 2016-08-01 2020-07-03 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
CN106924241A (zh) * 2017-04-28 2017-07-07 广州医科大学 川陈皮素在预防或治疗心衰药物中的应用
KR20220009440A (ko) 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
US12453719B2 (en) 2019-05-30 2025-10-28 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor
CN115487175B (zh) * 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
TWI894333B (zh) * 2020-08-17 2025-08-21 大陸商深圳信立泰藥業股份有限公司 血管收縮素ii受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用

Also Published As

Publication number Publication date
CN115487175B (zh) 2024-05-14
TW202114652A (zh) 2021-04-16
KR20220012317A (ko) 2022-02-03
EP4032532A1 (en) 2022-07-27
CN113286585B (zh) 2022-11-08
KR102752382B1 (ko) 2025-01-09
CN113286585A (zh) 2021-08-20
US20220395491A1 (en) 2022-12-15
CO2022004910A2 (es) 2022-05-31
CN115487175A (zh) 2022-12-20
TWI809313B (zh) 2023-07-21
US12508246B2 (en) 2025-12-30
CA3151788A1 (en) 2021-03-25
AU2020348813A1 (en) 2022-04-14
WO2021052441A1 (zh) 2021-03-25
MX2022003408A (es) 2022-07-12
EP4032532A4 (en) 2023-10-04
AU2020348813B2 (en) 2025-09-11
JP2022545904A (ja) 2022-11-01
JP7316449B2 (ja) 2023-07-27
ZA202204370B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
CO2023011071A2 (es) Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
CL2017003351A1 (es) Anticuerpo anti receptor de transferrina humana que pasan a través de la barrera hematoencefálica.
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
AR111360A1 (es) Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
ECSP22031078A (es) Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia card?aca
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
PE20211196A1 (es) Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
NI201900080A (es) Moduladores del receptor de estrógeno
CO7461127A2 (es) Código para la configuración de un dispositivo de atención al paciente
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
MX376160B (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta2 adrenérgico.
BR112016028614A8 (pt) novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso
CO6640306A2 (es) Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso